XML 59 R43.htm IDEA: XBRL DOCUMENT v3.5.0.2
Agreements - CytomX (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended 30 Months Ended
Jan. 31, 2014
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2014
Sep. 30, 2014
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2016
Dec. 31, 2006
Collaborative Agreements disclosures                            
Long-term deferred revenue   $ 19,288,000       $ 40,855,000       $ 19,288,000 $ 40,855,000   $ 19,288,000  
Deferred revenue, net of current portion   19,288,000       40,855,000       19,288,000 40,855,000   19,288,000  
Costs related to the research and development services   38,652,000 $ 36,094,000 $ 38,199,000 $ 35,132,000 $ 30,437,000 $ 25,666,000 $ 27,647,000 $ 28,018,000 148,077,000 111,768,000 $ 106,958,000    
Development and Commercialization License | Development milestones                            
Collaborative Agreements disclosures                            
Potential milestone payments                           $ 4,500,000
CytomX                            
Collaborative Agreements disclosures                            
Costs related to the research and development services                   868,000 $ 130,000 0    
CytomX | Right-to-test agreement                            
Collaborative Agreements disclosures                            
Potential milestone payments $ 160,000,000                          
Potential milestone payments to be paid $ 80,000,000                          
Estimated utilization period after commercialization 10 years                          
Discount rate (as a percent) 13.00%                          
Value of collaborators licenses   13,100,000               13,100,000     13,100,000  
Estimated term of development and commercialization license 25 years                          
Fair value of consideration for services received $ 13,100,000                          
CytomX | Right-to-test agreement | Development milestones                            
Collaborative Agreements disclosures                            
Potential milestone payments 10,000,000                          
Potential milestone payments to be paid 7,000,000                          
Fair value of consideration for services provided                         12,700,000  
CytomX | Right-to-test agreement | Phase I clinical trial                            
Collaborative Agreements disclosures                            
Potential milestone payments   1,000,000               1,000,000     1,000,000  
Potential milestone payments to be paid   1,000,000               1,000,000     1,000,000  
CytomX | Right-to-test agreement | Future Technological Improvements                            
Collaborative Agreements disclosures                            
Value of collaborators licenses   13,000,000               13,000,000     13,000,000  
Fair value of consideration for services provided                         350,000  
CytomX | Right-to-test agreement | Research Services                            
Collaborative Agreements disclosures                            
Value of collaborators licenses   $ 140,000               $ 140,000     140,000  
Fair value of consideration for services provided                         $ 140,000  
Fair value of consideration for services received 310,000                     $ 12,800,000    
CytomX | Right-to-test agreement | Regulatory milestones                            
Collaborative Agreements disclosures                            
Potential milestone payments 50,000,000                          
Potential milestone payments to be paid 23,000,000                          
CytomX | Right-to-test agreement | Sales milestones                            
Collaborative Agreements disclosures                            
Potential milestone payments 100,000,000                          
Potential milestone payments to be paid $ 50,000,000